BRIEF-Merck provides update on Anacetrapib development program
October 11, 2017 at 17:07 PM EDT
* Merck & Co Inc - Decision follows a thorough review of clinical profile of Anacetrapib, including discussions with external experts
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.